The White House estimates the program will save federal and state governments a combined $64.3 billion over the next decade by requiring drug manufacturers to offer the lowest price they sell to any state to every state participating in the scheme.
Health‑policy experts, however, caution that the projected savings may not translate into lower out‑of‑pocket costs for patients, especially those covered by Medicaid, whose drug prices are already heavily discounted.
Brian Reid, principal at health‑consultancy Reid Strategic, told reporters that the Centers for Medicare and Medicaid Services’ “GENEROUS” initiative “is not going to make medicines more affordable” for Medicaid beneficiaries and that any benefit would likely be limited to modest savings for the Medicaid programs themselves.
The details of the plan remain vague. Officials have not disclosed which specific drugs will be subject to the most‑favored‑nation pricing or how individual states will implement the pricing mandates.
Peter Maybarduk, director of Access to Medicines at advocacy group Public Citizen, questioned the administration’s ten‑year savings estimate, noting that the confidential pricing deals could expire at the end of Trump’s term, potentially undermining the projected long‑term savings.
If the program proceeds as announced, it could reshape negotiations between state Medicaid agencies and pharmaceutical companies, but its real impact on consumer drug costs and the sustainability of the pricing agreements remains uncertain.